SCHEMBL21872013

SCHEMBL21872013

COc1ccc2c(c1C(C)C)CCCC2

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
CES1 P23141 1/20 0.39
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
ADRA1A P35348 1/20 0.37
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
CETP P11597 1/20 0.36
PNMT P11086 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19869254 0.96 HTR2C (0.39) HTR2AHTR2CHTR2BCES1TLR9
SCHEMBL22102571 0.83 ADRA1A (0.38) HTR2AHTR2CHTR2BADRA1AALDH1A1
SCHEMBL17770807 0.77 KDM4E (0.46) HTR2AHTR2CHTR2BCES1ADRA1A
SCHEMBL4127686 0.76 ADRA1A (0.39) HTR2AHTR2CHTR2BCES1ADRA1A
SCHEMBL21872026 0.76 HTR2A (0.42) HTR2AHTR2CHTR2BCES1ADRA1A
SCHEMBL8960045 0.76 KDM4E (0.49) HTR2AHTR2CHTR2BADRA1AALDH1A1
SCHEMBL22103244 0.74 HTR2A (0.41) HTR2AHTR2CHTR2BADRA1AALDH1A1
SCHEMBL19432994 0.74 HTR2A (0.41) HTR2AHTR2CHTR2BCES1ADRA1A
SCHEMBL19695769 0.74 BCL2L1 (0.47) CES1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6168691 0.74 HTR2A (0.41) HTR2AHTR2CHTR2BADRA1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021219072-A1 PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR 上海科州药物研发有限公司 (CN) 2021-11-04 WO disclosed
US-20200131144-A1 AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS PHENEX-FXR GMBH (DE) 2020-04-30 US disclosed
US-20200115357-A1 LIVER X RECEPTORS (LXR) MODULATORS PHENEX-FXR GMBH (DE) 2020-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131144-A1 AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS NR1H2, NR1H3, NR1H4 HTR2A 1490/4885HTR2C 2235/4885HTR2B 1799/4885
US-20200115357-A1 LIVER X RECEPTORS (LXR) MODULATORS NR1H2, NR1H3, NR1H4 HTR2A 1671/4885HTR2C 2322/4885HTR2B 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.